CN114945595A - 抗lag3单克隆抗体及其制备方法和应用 - Google Patents

抗lag3单克隆抗体及其制备方法和应用 Download PDF

Info

Publication number
CN114945595A
CN114945595A CN202180008891.3A CN202180008891A CN114945595A CN 114945595 A CN114945595 A CN 114945595A CN 202180008891 A CN202180008891 A CN 202180008891A CN 114945595 A CN114945595 A CN 114945595A
Authority
CN
China
Prior art keywords
antibody
lag
lag3
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180008891.3A
Other languages
English (en)
Chinese (zh)
Inventor
宋戈
肖辉
何虹霖
许旭
姜伟东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Fuhong Hanlin Biopharmacy Co ltd
Shanghai Henlius Biotech Inc
Original Assignee
Shanghai Fuhong Hanlin Biopharmacy Co ltd
Shanghai Henlius Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fuhong Hanlin Biopharmacy Co ltd, Shanghai Henlius Biotech Inc filed Critical Shanghai Fuhong Hanlin Biopharmacy Co ltd
Publication of CN114945595A publication Critical patent/CN114945595A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180008891.3A 2020-01-21 2021-01-19 抗lag3单克隆抗体及其制备方法和应用 Pending CN114945595A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010069008 2020-01-21
CN2020100690089 2020-01-21
PCT/CN2021/072610 WO2021147837A1 (zh) 2020-01-21 2021-01-19 抗lag3单克隆抗体及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN114945595A true CN114945595A (zh) 2022-08-26

Family

ID=76993109

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180008891.3A Pending CN114945595A (zh) 2020-01-21 2021-01-19 抗lag3单克隆抗体及其制备方法和应用

Country Status (10)

Country Link
US (1) US20230074657A1 (cg-RX-API-DMAC10.html)
EP (1) EP4095159A4 (cg-RX-API-DMAC10.html)
JP (1) JP7692918B6 (cg-RX-API-DMAC10.html)
KR (1) KR20220131279A (cg-RX-API-DMAC10.html)
CN (1) CN114945595A (cg-RX-API-DMAC10.html)
AU (1) AU2021210029A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022013544A2 (cg-RX-API-DMAC10.html)
CA (1) CA3165211A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021147837A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202208339B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
EP4410835A4 (en) * 2021-09-29 2025-09-24 Akeso Biopharma Inc ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
WO2023138677A1 (en) * 2022-01-24 2023-07-27 Crown Bioscience Inc. (Taicang) Novel anti-lag3 antibodies and derivative products
CN119950708B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109923126A (zh) * 2016-09-16 2019-06-21 上海复宏汉霖生物技术股份有限公司 抗-pd-1抗体
CN110621337A (zh) * 2017-05-10 2019-12-27 时迈药业 抗lag3人单克隆抗体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN114853891A (zh) * 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US20190330336A1 (en) * 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
UA128387C2 (uk) * 2017-04-05 2024-07-03 Ф. Хоффманн-Ля Рош Аг Антитіло до lag3
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
CN110204614B (zh) 2018-02-28 2022-07-12 广州誉衡生物科技有限公司 抗人lag-3单克隆抗体及其制备方法和用途
CN110305215B (zh) 2018-03-20 2023-11-03 基石药业 新型抗lag-3抗体多肽
CN110343179B (zh) 2018-04-02 2024-03-08 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
CN110172099B (zh) 2018-08-16 2020-03-03 上海健信生物医药科技有限公司 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109923126A (zh) * 2016-09-16 2019-06-21 上海复宏汉霖生物技术股份有限公司 抗-pd-1抗体
CN110621337A (zh) * 2017-05-10 2019-12-27 时迈药业 抗lag3人单克隆抗体及其用途

Also Published As

Publication number Publication date
EP4095159A1 (en) 2022-11-30
EP4095159A4 (en) 2024-03-20
CA3165211A1 (en) 2021-07-29
US20230074657A1 (en) 2023-03-09
AU2021210029A1 (en) 2022-09-01
JP7692918B2 (ja) 2025-06-16
ZA202208339B (en) 2023-11-29
JP7692918B6 (ja) 2025-07-17
KR20220131279A (ko) 2022-09-27
JP2023510982A (ja) 2023-03-15
BR112022013544A2 (pt) 2022-09-06
WO2021147837A1 (zh) 2021-07-29

Similar Documents

Publication Publication Date Title
CN111601825A (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
JP2022502371A5 (cg-RX-API-DMAC10.html)
CN115734972A (zh) 抗cd73抗体及其用途
JP2020501532A5 (cg-RX-API-DMAC10.html)
JP2023540732A5 (cg-RX-API-DMAC10.html)
CN115551888A (zh) 抗cd73抗体及其用途
Kunamneni et al. Ribosome display technology: applications in disease diagnosis and control
JP2019525914A5 (cg-RX-API-DMAC10.html)
CN111542546A (zh) 抗lag-3 抗体及其用途
JP2020511115A5 (cg-RX-API-DMAC10.html)
CN110198739A (zh) 一种pd-l1抗体药物组合物及其用途
CN111315886A (zh) 重组人碱性成纤维细胞生长因子(rh-bFGF)以及包含rh-bFGF的药物组合物
ZA202208339B (en) Anti-lag3 monoclonal antibody, and preparation method therefor and use thereof
CN115803343A (zh) 多特异性抗体及其应用
CN110799522A (zh) 用于治疗、改善或预防脑出血的肽及其用途
CN116133677A (zh) 新型多肽制剂及其治疗用途
CN115461370A (zh) St2抗原结合蛋白
CN110036108A (zh) 一种细菌β-1,3-葡聚糖酶及其编码基因与应用
JP2022529789A5 (cg-RX-API-DMAC10.html)
CN102703455A (zh) 一种人心肌肌钙蛋白i适配子及筛选方法和应用
Distelhorst et al. The variable internal structure of the Mycoplasma penetrans attachment organelle revealed by biochemical and microscopic analyses: implications for attachment organelle mechanism and evolution
CN116113429A (zh) 新型多肽及其治疗用途
Vlachonikola et al. T Cell defects and immunotherapy in chronic lymphocytic leukemia
CN115315445A (zh) 一种靶向人cd47的单域抗体及其用途
JP2009544304A5 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079690

Country of ref document: HK